Following Two Years of Work With The FDA, 23andMe Announces New Customer Experience As Personal Genome Service

23andMe, Inc., the leading personal genetics company, today announced the launch of their new Personal Genome Service (PGS). Following two years of work with the FDA, extensive user comprehension testing and a complete redesign, 23andMe is launching an entirely new experience that includes carrier status, wellness, trait and ancestry reports. Experience

Lancet Oncology Commission Report Insists For Global Approach to Radiotherapy

Increasing access to radiotherapy worldwide through greater investment could save millions of lives, according to The Lancet Oncology Commission's report presented at the 2015 European Cancer Congress in Vienna, Austria, and published in The Lancet Oncology. The Commission's results were presented here yesterday at the 2015 annual meeting of the

Cancer Patients Report Improved Function And Well-Being With Telotristat Etiprate Therapy By Lexicon

Lexicon Pharmaceuticals, Inc.'s (Nasdaq: LXRX) telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine

Positive Preclinical Data on VAL-083 Presented by DelMar Pharmaceuticals for Ovarian Cancer

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced that yesterday it presented positive preclinical data demonstrating the promising potential of its lead product candidate VAL-083 (dianhydrogalactitol) as a treatment for ovarian cancer.

Ahead of World Osteoporosis Day, Recent Study Shows Significant Results to Reversing Bone Loss by Non-Pharmaceutical Approach

Ahead of World Osteoporosis Day on October 20, 2015, excitement is growing over a recent study which shows significant success in reversing bone loss, without the use of pharmaceutical products. In light of the concerns surrounding serious side effects of osteoporosis drugs, it is welcome news that the osteogenic loading

Allergan Presents Harmony Data at American Society of Dermatologic Surgery Meeting

Allergan plc (NYSE: AGN) presented the results of its HARMONY study at the American Society of Dermatologic Surgery Meeting in Chicago this past weekend. Dr. Susan Weinkle, past president of ASDS, presented a paper titled 'Substantial Improvements in Subject-Assessed Satisfaction with Appearance and Psychological Impact from Combined Facial Aesthetic Treatment